Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | HTR2B | P41595 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | TDO2 | P48775 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29707581 | 1.00 | PNMT (0.56) | PNMTHTR2AHTR2BHTR2CIDO1 | |
| SCHEMBL1727844 | 1.00 | PNMT (0.56) | PNMTHTR2AHTR2BHTR2CIDO1 | |
| SCHEMBL1730002 | 1.00 | PNMT (0.56) | PNMTHTR2AHTR2BHTR2CIDO1 | |
| SCHEMBL2399603 | 0.86 | PNMT (0.53) | PNMTHTR2AHTR2BHTR2CIDO1 | |
| SCHEMBL12065005 | 0.86 | PNMT (0.53) | PNMTHTR2AHTR2BHTR2CIDO1 | |
| SCHEMBL734654 | 0.84 | PNMT (0.67) | PNMTHTR2AHTR2BHTR2CIDO1 | |
| SCHEMBL20792210 | 0.84 | PNMT (0.67) | PNMTHTR2AHTR2BHTR2CIDO1 | |
| SCHEMBL1730600 | 0.83 | EPHX1 (0.51) | PNMTHTR2AHTR2BHTR2CIDO1 | |
| SCHEMBL1730389 | 0.83 | EPHX1 (0.51) | PNMTHTR2AHTR2BHTR2CIDO1 | |
| SCHEMBL20993283 | 0.83 | PNMT (0.53) | PNMTHTR2AHTR2BHTR2CIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4125840-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | Som Innovation Biotech, S.A. (ES) | 2023-02-08 | — | — | EP | disclosed |
| CN-114805342-A | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and use thereof | 赛弗卢尔生命科学公司 | 2022-07-29 | — | — | CN | disclosed |
| WO-2019233457-A1 | ERK INHIBITOR AND USE THEREOF | 贝达药业股份有限公司 (CN) | 2019-12-12 | — | — | WO | disclosed |
| WO-2019233456-A1 | ERK INHIBITOR AND USE THEREOF | 贝达药业股份有限公司 (CN) | 2019-12-12 | — | — | WO | disclosed |
| CN-108883399-A | Fenfluramine composition and preparation method thereof | 周格尼克斯国际有限公司 | 2018-11-23 | — | — | CN | disclosed |
| US-9751843-B2 | Substituted uracils and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-05 | — | — | US | disclosed |
| US-20160297771-A1 | SUBSTITUTED URACILS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-13 | — | — | US | disclosed |
| CN-105980381-A | Substituted uracils and use thereof | 拜耳医药股份有限公司 | 2016-09-28 | — | — | CN | disclosed |
| WO-2013104577-A1 | BENZIMIDAZOLYL-ACETAMIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | ACESION PHARMA APS (DK) | 2013-07-18 | — | — | WO | disclosed |
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | SCHERING CORPORATION (US) | 2011-09-01 | — | — | US | disclosed |
| US-7368573-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. | 2008-04-17 | — | — | US | disclosed |
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. | 2008-04-17 | — | — | US | disclosed |
| US-7338968-B2 | Thiadiazoles AS CXC- and CC- chemokine receptor ligands | SCHERING CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070264230-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION | 2007-11-15 | — | — | US | disclosed |
| US-20070264230-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION | 2007-11-15 | — | — | US | disclosed |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2007-04-26 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | BERTINATO PETER | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | CCR2, ACKR3, CX3CR1 | PNMT 4846/4885HTR2A 1287/4885HTR2B 761/4885 |
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | CCR1, ACKR3, CXCR1 | PNMT 4808/4885HTR2A 3747/4885HTR2B 2523/4885 |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, ACKR3, CXCR1 | PNMT 4808/4885HTR2A 3747/4885HTR2B 2523/4885 |
| US-20160297771-A1 | SUBSTITUTED URACILS AND USE THEREOF | UNG, UMPS, TYMP | PNMT 1226/4885HTR2A 3904/4885HTR2B 3245/4885 |
| US-20070264230-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | CXCR1, CCR2, CX3CR1 | PNMT 4857/4885HTR2A 1740/4885HTR2B 1023/4885 |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | APOB, MTPN, CTRB1 | PNMT 2124/4885HTR2A 1119/4885HTR2B 97/4885 |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | APOB, MTPN, CTRB1 | PNMT 2124/4885HTR2A 1119/4885HTR2B 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.